Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Dysfunctional HDL and atherosclerotic cardiovascular disease.

Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR.

Nat Rev Cardiol. 2016 Jan;13(1):48-60. doi: 10.1038/nrcardio.2015.124. Epub 2015 Sep 1. Review.

2.

JCL roundtable: HDL in the primary care setting.

Brown WV, Ansell BJ, Mackey RH, Toth PP.

J Clin Lipidol. 2014 Jul-Aug;8(4):364-72. doi: 10.1016/j.jacl.2014.05.009. Epub 2014 Jun 18. Review.

PMID:
25110217
3.

Clinical decisions. The guidelines battle on starting statins.

D'Agostino RB Sr, Ansell BJ, Mora S, Krumholz HM.

N Engl J Med. 2014 Apr 24;370(17):1652-8. doi: 10.1056/NEJMclde1314766. No abstract available.

PMID:
24758622
4.

Neisseria lactamica arthritis and septicemia complicating myeloma.

Everts RJ, Speers D, George ST, Ansell BJ, Karunajeewa H, Ramos RD.

J Clin Microbiol. 2010 Jun;48(6):2318. doi: 10.1128/JCM.02132-09. Epub 2010 Apr 21. No abstract available.

5.

A review of trials evaluating nonstatin lipid-lowering therapies.

Ansell BJ.

Curr Atheroscler Rep. 2009 Jan;11(1):64-6. Review.

PMID:
19080730
6.

Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis.

Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M.

Arthritis Res Ther. 2008;10(4):213. doi: 10.1186/ar2471. Epub 2008 Aug 29. Review.

7.

Not getting to goal: the clinical costs of noncompliance.

Ansell BJ.

J Manag Care Pharm. 2008 Jul;14(6 Suppl B):9-15.

8.

Hyperlipidaemia and cardiovascular disease.

Ansell BJ.

Curr Opin Lipidol. 2008 Aug;19(4):433-4. doi: 10.1097/MOL.0b013e328308b63d. No abstract available.

PMID:
18607193
9.

Targeting the anti-inflammatory effects of high-density lipoprotein.

Ansell BJ.

Am J Cardiol. 2007 Dec 3;100(11 A):n3-9. Review.

PMID:
18047850
10.

The two faces of the 'good' cholesterol.

Ansell BJ.

Cleve Clin J Med. 2007 Oct;74(10):697-700, 703-5. Review.

PMID:
17941290
11.

High-density lipoprotein as a therapeutic target: a systematic review.

Singh IM, Shishehbor MH, Ansell BJ.

JAMA. 2007 Aug 15;298(7):786-98. Review. Erratum in: JAMA. 2007 Oct 3;298(13):1516.

PMID:
17699012
12.

The paradox of dysfunctional high-density lipoprotein.

Ansell BJ, Fonarow GC, Fogelman AM.

Curr Opin Lipidol. 2007 Aug;18(4):427-34. Review.

PMID:
17620860
13.

Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study.

Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, Paulus HE, Park GS, Gong T, Ansell BJ.

J Rheumatol. 2007 Jul;34(7):1459-64. Epub 2007 Jun 1.

PMID:
17552046
14.

HDL function as a target of lipid-modifying therapy.

Watson KE, Ansell BJ, Watson AD, Fonarow GC.

Rev Cardiovasc Med. 2007 Winter;8(1):1-8. Review.

PMID:
17401296
15.

Modifying the anti-inflammatory effects of high-density lipoprotein.

Ansell BJ, Fonarow GC, Navab M, Fogelman AM.

Curr Atheroscler Rep. 2007 Jan;9(1):57-63. Review.

PMID:
17169248
16.

Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey.

Ansell BJ, Fonarow GC, Maki KC, Dicklin MR, Bell M, Davidson MH; NEPTUNE II Steering Committee.

Am Heart J. 2006 Nov;152(5):976-81.

PMID:
17070174
17.

Mechanisms of disease: proatherogenic HDL--an evolving field.

Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM.

Nat Clin Pract Endocrinol Metab. 2006 Sep;2(9):504-11. Review.

PMID:
16957764
18.

High-density lipoprotein: is it always atheroprotective?

Ansell BJ, Fonarow GC, Fogelman AM.

Curr Atheroscler Rep. 2006 Sep;8(5):405-11. Review.

PMID:
16901411
19.

High-density lipoprotein function recent advances.

Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC.

J Am Coll Cardiol. 2005 Nov 15;46(10):1792-8. Epub 2005 Oct 19. Review.

20.

Evidence for a combined approach to the management of hypertension and dyslipidemia.

Ansell BJ.

Am J Hypertens. 2005 Sep;18(9 Pt 1):1249-57. Review.

PMID:
16245413
21.

Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.

Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM.

Am J Cardiol. 2005 Aug 15;96(4):556-63.

PMID:
16098311
22.

The double jeopardy of HDL.

Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, Hough G, Bachini E, Grijalva VR, Wagner AC, Shaposhnik Z, Fogelman AM.

Ann Med. 2005;37(3):173-8. Review.

PMID:
16019715
23.

Apolipoprotein A-I mimetic peptides.

Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM.

Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1325-31. Epub 2005 Apr 14. Review.

PMID:
15831812
24.

Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.

Ansell BJ.

Curr Atheroscler Rep. 2005 Feb;7(1):29-33. Review.

PMID:
15683599
25.

Anti-inflammatory properties of HDL.

Ansell BJ, Navab M, Watson KE, Fonarow GC, Fogelman AM.

Rev Endocr Metab Disord. 2004 Dec;5(4):351-8. Review. No abstract available.

PMID:
15486468
26.

The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.

Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM.

J Lipid Res. 2004 Jun;45(6):993-1007. Epub 2004 Apr 1. Review.

27.

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.

Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM.

Circulation. 2003 Dec 2;108(22):2751-6. Epub 2003 Nov 24.

PMID:
14638544
29.

Reassessment of National Cholesterol Education Program Adult Treatment Panel-III guidelines: one year later.

Ansell BJ, Waters DD; National Cholesterol Education Program Adult Treatment Panel-III Guidelines.

Am J Cardiol. 2002 Sep 1;90(5):524-5. No abstract available.

PMID:
12208415
30.

Improvement in current approaches to lipid lowering.

Ansell BJ.

Am Fam Physician. 2002 Mar 1;65(5):783, 786-7. No abstract available.

31.
32.

Developing a clinical strategy for cholesterol management in an era of unanswered questions.

Ansell BJ.

Am J Cardiol. 2001 Aug 16;88(4A):25F-30F. Review.

PMID:
11520484
33.

Appropriate first-line lipid-lowering therapy for type 1 diabetes mellitus.

Ansell BJ.

Arch Intern Med. 2001 Jun 11;161(11):1461-2. No abstract available.

PMID:
11386905
34.

Cholesterol, stroke risk, and stroke prevention.

Ansell BJ.

Curr Atheroscler Rep. 2000 Mar;2(2):92-6. Review.

PMID:
11122730
35.

An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program.

Ansell BJ, Watson KE, Fogelman AM.

JAMA. 1999 Dec 1;282(21):2051-7. Review.

PMID:
10591388
36.

Visual tracking behavior in low functioning head-injured adults.

Ansell BJ.

Arch Phys Med Rehabil. 1995 Aug;76(8):726-31.

PMID:
7632127
37.

Slow-to-recover brain-injured patients: rationale for treatment.

Ansell BJ.

J Speech Hear Res. 1991 Oct;34(5):1017-22. Review.

PMID:
1749232
38.
39.

Aphasic adults' use of heuristic and structural linguistic cues for sentence analysis.

Ansell BJ, Flowers CR.

Brain Lang. 1982 May;16(1):61-72. No abstract available.

PMID:
7104682
40.

Aphasic adults' understanding of complex adverbial sentences.

Ansell BJ, Flowers CR.

Brain Lang. 1982 Jan;15(1):82-91. No abstract available.

PMID:
7059793

Supplemental Content

Loading ...
Support Center